Amdinocillin Pivoxil

Summary

Amdinocillin Pivoxil (CHEMBL1650818) is an approved small molecule (ATC J01CA08); indicated across 2 conditions including bacterial infectious disease and urinary tract infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CA08
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 439.6 Da · C21H33N3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1650818
Name	Amdinocillin Pivoxil
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	115163
ATC	J01CA08
Molecular formula	C21H33N3O5S
Molecular weight	439.6
InChIKey	NPGNOVNWUSPMDP-HLLBOEOZSA-N

SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)OCOC(=O)C(C)(C)C)C

IUPAC name: 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

Also known as: Amdinocillin pivoxil, Pivmecilinam, Pivmecillinam, Pivmecillinam hydrochloride, Pivya, Selexid, AMDINOCILLIN PIVOXIL, PIVMECILLINAM, PIVMECILLINAM (HYDROCHLORIDE), pivmecillinam, Pivmecillinam (hydrochloride)

Parent form; salt/anhydrous children: CHEMBL4303519

Patent coverage: 1,424 distinct patent families (5,471 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM2	5.44	AC50	3599	nM	CHEMBL_ACT_25195660

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
urinary tract infection	4	MONDO:0100338	EFO:0003103

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE4	5
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06709196	PHASE4	RECRUITING	Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
NCT07236944	PHASE4	RECRUITING	Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care
NCT03228108	PHASE4	COMPLETED	Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.
NCT03282006	PHASE4	COMPLETED	Treating Pyelonephritis an Urosepsis With Pivmecillinam
NCT04959331	PHASE4	COMPLETED	Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.
NCT05545137	PHASE3	COMPLETED	Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection
NCT07407673	PHASE2	NOT_YET_RECRUITING	Prediction and Prevention of Bloodstream Infections After Kidney Transplantation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).